Viridian Therapeutics Secures Over $500M in Financing, Advances Key Clinical Programs for Thyroid Eye Disease

summarizeSummary

Viridian Therapeutics reported significant capital raises exceeding $500 million in 2025, alongside major clinical advancements for its thyroid eye disease (TED) pipeline, including a PDUFA date for veligrotug and completed Phase 3 enrollment for elegrobart, extending its financial runway.

check_boxKey Events · Financing and Capital Events · VRDN

• Significant Capital Raises

  The company raised approximately $289.1 million from a public offering in October 2025, $61.8 million from at-the-market offerings in 2025, received a $70.0 million upfront payment from a collaboration with Kissei Pharmaceutical, and $55.0 million from a revenue participation agreement with DRI Healthcare Acquisitions, totaling over $500 million in new capital.

• Veligrotug Regulatory Progress

  The Biologics License Application (BLA) for veligrotug was submitted to the FDA in October 2025, accepted for filing, and granted Priority Review in December 2025, with a PDUFA target action date of June 30, 2026. A Marketing Authorization Application (MAA) was also submitted to the EMA in January 2026.

• Elegrobart Clinical Advancement

  Enrollment was completed in September 2025 for two pivotal Phase 3 clinical trials (REVEAL-1 and REVEAL-2) for elegrobart, with topline data anticipated in Q1 2026 and Q2 2026, respectively.

• Extended Financial Runway

  Management expects existing cash, cash equivalents, marketable securities, potential near-term milestones, and anticipated revenues to fund planned operations to break even, extending the financial runway beyond 12 months.

auto_awesomeAnalysis · VRDN · Life Sciences

Viridian Therapeutics' annual report highlights substantial financial and clinical progress in 2025. The company successfully raised over $500 million through a public offering, at-the-market sales, an upfront payment from a collaboration agreement with Kissei, and an initial payment from a revenue participation agreement with DRI Healthcare Acquisitions. Concurrently, Viridian advanced its lead product candidate, veligrotug, by submitting a Biologics License Application (BLA) to the FDA, which was granted Priority Review with a PDUFA target action date of June 30, 2026, and also submitted a Marketing Authorization Application (MAA) to the EMA. Its second product candidate, elegrobart, completed enrollment for two pivotal Phase 3 clinical trials, with topline data expected in Q1 and Q2 2026. These achievements significantly extend the company's financial runway beyond 12 months and de-risk its near-term operational outlook, positioning it for potential commercialization.